Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Launched by ABBVIE · Jan 14, 2022
Trial Information
Current as of July 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Must provide written, signed informed consent for this study.
- • 2. Must have been enrolled in a previous clinical study of RGX-314 in the treatment of nAMD and must have received an SCS injection of RGX-314 in that study.
- • 3. Must be willing and able to comply with all study procedures.
- Exclusion Criteria:
- • 1. None
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Baltimore, Maryland, United States
Beverly Hills, California, United States
Poway, California, United States
Santa Barbara, California, United States
Bakersfield, California, United States
Nashville, Tennessee, United States
Reno, Nevada, United States
Phoenix, Arizona, United States
Santa Barbara, California, United States
Boston, Massachusetts, United States
Reno, Nevada, United States
The Woodlands, Texas, United States
Albuquerque, New Mexico, United States
Phoenix, Arizona, United States
Bakersfield, California, United States
Beverly Hills, California, United States
Mountain View, California, United States
Poway, California, United States
Augusta, Georgia, United States
Albuquerque, New Mexico, United States
Philadelphia, Pennsylvania, United States
Germantown, Tennessee, United States
Nashville, Tennessee, United States
The Woodlands, Texas, United States
Baltimore, Maryland, United States
Mountain View, California, United States
Augusta, Georgia, United States
Edina, Minnesota, United States
Philadelphia, Pennsylvania, United States
Germantown, Tennessee, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials